Royal Bank of Canada Lowers Stock Position in AngioDynamics, Inc. $ANGO

Royal Bank of Canada lessened its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 34.7% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 71,872 shares of the medical instruments supplier’s stock after selling 38,125 shares during the period. Royal Bank of Canada’s holdings in AngioDynamics were worth $817,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Farther Finance Advisors LLC increased its stake in shares of AngioDynamics by 146.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 1,199 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in AngioDynamics during the 4th quarter valued at about $27,000. State of Wyoming purchased a new position in AngioDynamics during the 2nd quarter valued at about $31,000. Russell Investments Group Ltd. boosted its stake in AngioDynamics by 329.5% during the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 3,213 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in AngioDynamics by 359.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock worth $54,000 after acquiring an additional 4,268 shares in the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 23,370 shares of the business’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the transaction, the senior vice president directly owned 64,745 shares in the company, valued at $953,046.40. The trade was a 26.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.00% of the stock is owned by company insiders.

AngioDynamics Stock Performance

Shares of ANGO stock opened at $15.75 on Friday. The company has a market capitalization of $650.95 million, a price-to-earnings ratio of -18.10 and a beta of 0.33. AngioDynamics, Inc. has a one year low of $9.06 and a one year high of $16.29. The company’s 50-day moving average is $13.96 and its 200 day moving average is $12.05.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.04. The business had revenue of $86.61 million during the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, research analysts predict that AngioDynamics, Inc. will post -0.25 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ANGO. HC Wainwright lifted their target price on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Zacks Research downgraded AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. Wall Street Zen raised AngioDynamics from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Canaccord Genuity Group lifted their price objective on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $19.50.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.